VYNE|Vyne Therapeutics Inc|Price:0.560|Chg%:0.00

More Details of Vyne Therapeutics Inc Company

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc Info



Ticker SymbolVYNE

Company nameVyne Therapeutics Inc

IPO dateJan 25, 2018

CEODomzalski (David)

Number of employees13

Security typeOrdinary Share

Fiscal year-endJan 25

Address685 Route 202/206 N., Suite 301

CityBRIDGEWATER

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code08807

Phone18007757936

Websitehttps://vynetherapeutics.com/

Ticker SymbolVYNE

IPO dateJan 25, 2018

CEODomzalski (David)

Company Executives of Vyne Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

104.92K

-7858.00%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

51.16K

-3579.00%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

41.85K

-2448.00%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Ms. Sharon Barbari

Independent Director

--

Mr. Patrick G. Lepore

Lead Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

104.92K

-7858.00%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

51.16K

-3579.00%

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

41.85K

-2448.00%

Mr. Steven L. Basta

Independent Director

7.45K

--

Ms. Elisabeth A. Sandoval Little

Independent Director

--

Mr. David Domzalski

President, Chief Executive Officer, Director

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2024

FY2023

FY2022

FY2021

FY2020

By BusinessUSD

Name

Revenue

Proportion

Royalty revenues

501.00K

0.00%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Royalty revenues

501.00K

0.00%

Shareholding Stats

Updated: Sat, Feb 7

Shareholders

Shareholder Types

Shareholders

Proportion

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

Other

88.75%

Shareholders

Proportion

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

Other

88.75%

Shareholder Types

Shareholders

Proportion

Hedge Fund

8.46%

Investment Advisor

3.54%

Corporation

3.35%

Investment Advisor/Hedge Fund

2.27%

Individual Investor

1.23%

Research Firm

0.45%

Other

80.70%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

88

4.85M

14.58%

-6.84M

2025Q3

84

8.51M

25.77%

-898.65K

2025Q2

84

9.46M

56.76%

-1.30M

2025Q1

81

9.36M

56.20%

-1.38M

2024Q4

92

9.37M

63.49%

-533.87K

2024Q3

88

8.98M

61.30%

-594.32K

2024Q2

89

9.65M

66.73%

+287.65K

2024Q1

92

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Access Industries, Inc.

1.12M

3.35%

--

Oct 15, 2025

Baker Bros. Advisors LP

851.35K

2.56%

+851.35K

--

Sep 30, 2025

Delaware Street Capital, L.L.C.

696.47K

2.09%

--

Sep 30, 2024

Acorn Capital Advisors, LLC

586.57K

1.76%

-150.00K

-20.36%

Sep 30, 2025

Shay Capital LLC

492.58K

1.48%

+492.58K

--

Sep 30, 2025

Acadian Asset Management LLC

446.41K

1.34%

+424.00K

+1891.32%

Sep 30, 2025

The Vanguard Group, Inc.

190.38K

0.57%

-305.91K

-61.64%

Sep 30, 2025

Ikarian Capital LLC

290.00K

0.87%

--

Sep 30, 2025

Two Sigma Investments, LP

277.39K

0.83%

+277.39K

--

Sep 30, 2025

Domzalski (David T)

152.86K

0.46%

-12.68K

-7.66%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Date

Ex-dividend Date

Type

Ratio

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1